Communiqués Alkermes plc

Actions

ALKS

IE00B56GVS15

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 13/08/2026			Varia. 5j.	Varia. 1 janv.
49,45 ^USD	-1,65%		+2,23%	+76,73%

04/08	Alkermes : une initiée cède pour 2 239 076 $ d'actions, selon un récent document de la SEC	MT
29/07	Alkermes : la solidité des activités de base porte les résultats du deuxième trimestre, le pipeline d'orexine comme catalyseur selon RBC	MT

Communiqués

28/07	Alkermes plc Reports Second Quarter 2026 Financial Results	BU
16/07	Alkermes to Report Second Quarter Financial Results on July 28, 2026	AQ
14/07	Alkermes to Report Second Quarter Financial Results on July 28, 2026	BU
13/07	Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis	BU
17/06	Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026	BU
15/06	Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe	BU
05/06	Alkermes to Present New Data on Alixorexton and LUMRYZ at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research	AQ
04/06	Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research	BU
03/06	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
26/05	Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting	BU
21/05	Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences	BU
12/05	Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia	BU
06/05	Alkermes : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Alkermes : ALKS Q1 2026 Earnings Call Prepared Remarks FINAL	PU
05/05	Alkermes : Q1 2026 Financial Results Press Release v2	PU
05/05	Alkermes : ALKS Q1 2026 Earnings Slides FINAL	PU
05/05	Alkermes: Q1 Earnings Snapshot	AQ
05/05	Alkermes plc Reports First Quarter 2026 Financial Results	BU
21/04	Alkermes to Report First Quarter Financial Results on May 5, 2026	BU
16/04	Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting	BU
14/04	Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry	BU
01/04	Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2	BU
12/03	Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program	BU
10/03	Alkermes to Present at the Stifel 2026 Virtual CNS Forum	BU
25/02	Alkermes : ALKS Q4 FY 2025 Earnings Call Prepared Remarks FINAL	PU